Christopher J Yates1, Spiros Fourlanos, Peter G Colman, Solomon J Cohney. 1. 1 Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia. 2 Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Victoria, Australia. 3 Department of Renal Medicine, Royal Melbourne Hospital, Parkville, Victoria, Australia. 4 Department of Medicine, NorthWest Academic Centre, University of Melbourne, St Albans, Victoria, Australia. 5 Address for correspondence: Dr. Christopher J. Yates, Department of Diabetes and Endocrinology, Royal Melbourne Hospital, University of Melbourne, Level 4 West, Grattan Street, Parkville, Victoria 3050, Australia.
Abstract
BACKGROUND: The sensitivity of fasting plasma glucose (FPG) in screening for new-onset diabetes after transplantation (NODAT) has been questioned, particularly in the presence of moderate-dose prednisolone, where peak plasma glucose occurs 7 to 8 hr after administration. Oral glucose tolerance testing (OGTT) has been mooted as an alternative but is inconvenient for patients. METHODS: We compared sensitivity of screening tests for NODAT at 6 weeks, 3 months, and 12 months after kidney transplantation in recipients receiving prednisolone, mycophenolate, and tacrolimus. RESULTS: At 6 weeks, NODAT (capillary blood glucose [CapBG] ≥11.1 mmol/L, FPG ≥7.0 mmol/L, 2-hr plasma glucose ≥11.1 mmol/L, or glycated hemoglobin [HbA1c] ≥6.5%) was detected in 46% with CapBG versus 12% with OGTT (P=0.013), 4% with HbA1c (P<0.001), and 0% with FPG (P<0.001; n=26). At 3 months, NODAT was present in 14% with HbA1c versus 20% with OGTT (P=0.600) and 2% with FPG (P=0.059; n=50), whereas, at 12 months, NODAT was found in 4% with HbA1c versus 6% with OGTT (P=1.00) and 2% with FPG (P=0.618; n=51). Combining 3- and 12-month data, OGTT recorded NODAT in 14% and impaired glucose tolerance in 28%, whereas HbA1c detected NODAT in 10% and impaired glucose tolerance (from ≥5.7 to <6.5%) in 51%. Employing HbA1c as a screening test and reserving OGTT for those with impaired glucose tolerance would detect NODAT with a sensitivity more than 94%, avoiding the need for OGTT in 49% of patients. CONCLUSIONS: This study confirms the inadequacy of FPG screening for NODAT in the first 6 weeks after transplantation, at which time 4 p.m. CapBG also outperformed OGTT. From 3 months, HbA1c had similar sensitivity to OGTT and represents a convenient alternative.
BACKGROUND: The sensitivity of fasting plasma glucose (FPG) in screening for new-onset diabetes after transplantation (NODAT) has been questioned, particularly in the presence of moderate-dose prednisolone, where peak plasma glucose occurs 7 to 8 hr after administration. Oral glucose tolerance testing (OGTT) has been mooted as an alternative but is inconvenient for patients. METHODS: We compared sensitivity of screening tests for NODAT at 6 weeks, 3 months, and 12 months after kidney transplantation in recipients receiving prednisolone, mycophenolate, and tacrolimus. RESULTS: At 6 weeks, NODAT (capillary blood glucose [CapBG] ≥11.1 mmol/L, FPG ≥7.0 mmol/L, 2-hr plasma glucose ≥11.1 mmol/L, or glycated hemoglobin [HbA1c] ≥6.5%) was detected in 46% with CapBG versus 12% with OGTT (P=0.013), 4% with HbA1c (P<0.001), and 0% with FPG (P<0.001; n=26). At 3 months, NODAT was present in 14% with HbA1c versus 20% with OGTT (P=0.600) and 2% with FPG (P=0.059; n=50), whereas, at 12 months, NODAT was found in 4% with HbA1c versus 6% with OGTT (P=1.00) and 2% with FPG (P=0.618; n=51). Combining 3- and 12-month data, OGTT recorded NODAT in 14% and impaired glucose tolerance in 28%, whereas HbA1c detected NODAT in 10% and impaired glucose tolerance (from ≥5.7 to <6.5%) in 51%. Employing HbA1c as a screening test and reserving OGTT for those with impaired glucose tolerance would detect NODAT with a sensitivity more than 94%, avoiding the need for OGTT in 49% of patients. CONCLUSIONS: This study confirms the inadequacy of FPG screening for NODAT in the first 6 weeks after transplantation, at which time 4 p.m. CapBG also outperformed OGTT. From 3 months, HbA1c had similar sensitivity to OGTT and represents a convenient alternative.
Authors: A Sharif; M Hecking; A P J de Vries; E Porrini; M Hornum; S Rasoul-Rockenschaub; G Berlakovich; M Krebs; A Kautzky-Willer; G Schernthaner; P Marchetti; G Pacini; A Ojo; S Takahara; J L Larsen; K Budde; K Eller; J Pascual; A Jardine; S J L Bakker; T G Valderhaug; T G Jenssen; S Cohney; M D Säemann Journal: Am J Transplant Date: 2014-08-06 Impact factor: 8.086
Authors: David Langsford; Varuni Obeyesekere; Sara Vogrin; Jessie Teng; Richard J MacIsaac; Glenn Ward; Frank Alford; Karen M Dwyer Journal: Transplant Direct Date: 2016-10-07
Authors: Johannes M Werzowa; Marcus D Säemann; Alexander Mohl; Michael Bergmann; Christopher C Kaltenecker; Wolfgang Brozek; Andreas Thomas; Michael Haidinger; Marlies Antlanger; Johannes J Kovarik; Chantal Kopecky; Peter X K Song; Klemens Budde; Julio Pascual; Manfred Hecking Journal: PLoS One Date: 2018-03-08 Impact factor: 3.240